Patent · US Active

Bispecific antigen binding molecules comprising anti-FAP clone 212

US12275794B2 · kind B2 · utility

0Cited by

13References

27Claims

0Family size

Assignee

Hoffmann-La Roche Inc. · US

Inventors

Peter Bruenker · Hittnau, CH
Harald Duerr · Starnberg, DE
Christian Klein · Iffeldorf, DE
Pablo Umana · Wollerau, CH
Alexander BUJOTZEK · Penzberg, DE
Joerg ZIELONKA · Schlieren, CH
Christine TRUMPFHELLER · Schlieren, CH
Moritz RAPP · Schlieren, CH
Marine LE CLECH · Schlieren, CH

Key dates

Filing date	Dec 21, 2021
Grant date	Apr 15, 2025
Priority date	—
Expiry date	Dec 21, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2319/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.